<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541138</url>
  </required_header>
  <id_info>
    <org_study_id>02191</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-02191</secondary_id>
    <secondary_id>CDR0000570253</secondary_id>
    <nct_id>NCT00541138</nct_id>
  </id_info>
  <brief_title>Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors</brief_title>
  <official_title>A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Tamoxifen may help carboplatin work better by making tumor cells more sensitive to&#xD;
      the drug.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving carboplatin and topotecan&#xD;
      together with tamoxifen and to see how well it works in treating patients with central&#xD;
      nervous system metastases or recurrent brain or spinal cord tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the systemic and CNS response rates and progression-free and overall&#xD;
           survival of patients with epithelial cancer and brain metastases treated with tamoxifen&#xD;
           citrate, topotecan hydrochloride, and carboplatin.&#xD;
&#xD;
        -  To evaluate the response rates, progression-free survival, and overall survival of&#xD;
           patients with recurrent primary glial tumors treated with this regimen.&#xD;
&#xD;
        -  To further assess the toxicity of these drugs in these patients.&#xD;
&#xD;
        -  To further evaluate the pharmacokinetics of topotecan hydrochloride and tamoxifen&#xD;
           citrate using paired specimens of cerebrospinal fluid and plasma from these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified by disease type (epithelial CNS metastases vs recurrent&#xD;
      glial tumors).&#xD;
&#xD;
      Patients receive topotecan IV on days 1-3 (72 hours), carboplatin IV over 30 minutes on day&#xD;
      4, and oral tamoxifen twice daily on days 1-7. Treatment repeats every 28 days in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients achieving a complete response (CR)&#xD;
      may be treated for 2 additional courses after documentation of CR.&#xD;
&#xD;
      Patients undergo blood sample collection at baseline and then periodically after the first&#xD;
      dose of topotecan to obtain plasma pharmacokinetic (PK) measurements of topotecan and&#xD;
      tamoxifen. Some patients may also undergo cerebrospinal fluid (CSF) collection to assess peak&#xD;
      CSF levels of topotecan and tamoxifen during course 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity profile as assessed by NCI CTC v2.0</measure>
    <time_frame>All patients who complete one course of therapy and are followed a minimum of 3 weeks after completion of first course of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate in patients with recurrent glial tumors as assessed by RECIST criteria</measure>
    <time_frame>All patients who complete at least one cycle of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate in patients with epithelial CNS metastases as assessed by RECIST criteria</measure>
    <time_frame>All patients who complete at least one cycle of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for going off-study</measure>
    <time_frame>Reported for all eligible patients</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression</measure>
    <time_frame>Reported for all eligible patients</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Reported for all eligible patients</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>CBDCA AUC=3</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Tamoxifen 100mg bid</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Topotecan 0.75 g/m2/d</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Epithelial neoplasms metastatic to the central nervous system&#xD;
&#xD;
                    -  Recurrent or refractory to prior chemotherapeutic or radiotherapeutic&#xD;
                       regimens or for which no standard chemotherapy or whole brain radiotherapy&#xD;
                       regimens exist&#xD;
&#xD;
                    -  Stage IV disease&#xD;
&#xD;
               -  Recurrent glial tumors (brain or spinal cord)&#xD;
&#xD;
          -  Received prior whole brain radiotherapy or stereotactic radiotherapy OR refused&#xD;
             radiotherapy&#xD;
&#xD;
               -  Patients with CNS metastases previously treated with radiotherapy are eligible,&#xD;
                  provided persistent or progressive CNS metastases are documented by MRI eight&#xD;
                  weeks after the end of radiotherapy&#xD;
&#xD;
               -  Patients with glial tumors must show progressive disease by MRI after prior&#xD;
                  radiotherapy&#xD;
&#xD;
          -  Measurable disease in the brain/leptomeninges of the brain or spinal cord with&#xD;
             baseline documentation within 4 weeks of study entry&#xD;
&#xD;
               -  Must have ≥ 1 lesion that is ≥ 1 cm on MRI scan&#xD;
&#xD;
          -  Ineligible for or has refused participation in higher priority institutional protocols&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 50-100%&#xD;
&#xD;
          -  Life expectancy ≥ 2 months&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  WBC 4,000/mm³ OR ANC ≥ 2,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST &lt; 2 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No nonmalignant concurrent illness (e.g., cardiovascular or pulmonary) that is either&#xD;
             poorly controlled with currently available treatment or of such severity to preclude&#xD;
             study entry&#xD;
&#xD;
          -  No severe infection&#xD;
&#xD;
          -  Patients who are ineligible for lumbar puncture are allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy, immunotherapy, or chemotherapy OR recovered&#xD;
             from expected side effects of prior therapy&#xD;
&#xD;
          -  No patients who are recovering from major surgery&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Concurrent steroid or anticonvulsant therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>adult mixed glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

